✦ LIBER ✦

829 The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘iressa’, ZD-1839) and the protein prenyltransferase inhibitor M365408 as potential therapeutics in bladder cancer

✍ Scribed by J.L. Dominguez-Escrig; J. Kelly; B.R. Davies

Book ID: 118646030
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 192 KB
Volume: 3
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(04)90821-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ZD1839 (Gefitinib, ‘Iressa’), an epiderm

ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma

✍ Fuminori Teraishi; Shunsuke Kagawa; Takanori Watanabe; Yasuhisa Tango; Takeshi K 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 444 KB

Ocular findings in patients with solid t

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials

✍ Murray, P I; Bristow, E; Forsythe, B J; Faulkner, K; Tullo, A B; Esmaeli, B 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 187 KB

Preclinical rationale for a combined tre

Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecan-refractory human colon cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 157 KB

880 Prostate cancer cell proliferation i

880 Prostate cancer cell proliferation is strongly reduced by combination treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’) and the anti -androgen bicalutamide (‘casodex’)

✍ M. Bologna; A. Angelucci; C. Festuccia; G.L. Gravina; P. Muzi; C. Vicentini 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant

Additive antitumor effects of the epider

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro

✍ Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Danilo Millimaggi; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 618 KB

## Abstract Progression from an androgen‐dependent to an androgen‐independent state often occurs in patients with prostate cancer (PCa) who undergo hormonal therapy. We have investigated whether inhibition of the epidermal growth factor receptor (EGFR) signaling pathway affects the antitumor effect